InflaRx (NASDAQ:IFRX) is one of the best penny stocks under $1 to buy now. As May came to an end, InflaRx announced that its ...

Key takeaways: Ulcerative pyoderma gangrenosum is a rare disease with no current treatment. Vilobelimab has been granted orphan drug and fast track designations by the FDA. InflaRx has initiated a ...

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.

The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ulcerative pyoderma gangrenosum (PG), a rare skin disorder characterized by chronic ...

Pustular pyoderma gangrenosum is common in people who have inflammatory bowel disease (IBD). Vegetative pyoderma gangrenosum: This type, also known as superficial pyoderma gangrenosum, causes ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...

Of all patients, 27% of patients had a history of PG or PG-like symptoms, 7.9% had a history of inflammatory bowel disease, and 4.8% had another systemic rheumatologic disease.

In a recently published systematic review, researchers determined that VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome typically presents in men, with atypical morphology ...